What are the dosing guidelines, contraindications, precautions, and monitoring recommendations for Ingrezza (valbenazine) in adult patients with tardive dyskinesia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ingrezza (Valbenazine) for Tardive Dyskinesia

Start Ingrezza at 40 mg once daily for one week, then increase to the target dose of 80 mg once daily for most patients with tardive dyskinesia. This dosing strategy is supported by FDA labeling and guideline recommendations that identify VMAT2 inhibitors as first-line treatment for moderate to severe or disabling tardive dyskinesia 1.

Dosing Guidelines

Standard Dosing for Tardive Dyskinesia

  • Initial dose: 40 mg once daily
  • After 1 week: Increase to 80 mg once daily (recommended target dose)
  • Alternative maintenance doses: 40 mg or 60 mg once daily may be considered based on individual response and tolerability 1

Administration

  • Take with or without food
  • INGREZZA SPRINKLE formulation can be opened and sprinkled over 1 tablespoon of soft food (applesauce, yogurt, pudding)—NOT milk or water
  • Swallow immediately or store mixture up to 2 hours at room temperature
  • Do not crush, chew, or administer via feeding tubes (risk of obstruction) 1

Dose Adjustments Required

Hepatic Impairment

Reduce to 40 mg once daily for moderate or severe hepatic impairment (Child-Pugh score 7-15) 1

CYP2D6 Poor Metabolizers

Reduce to 40 mg once daily for known poor metabolizers 1

Drug Interactions Requiring Dose Reduction

Reduce to 40 mg once daily when co-administered with:

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin)
  • Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine, quinidine) 1

Contraindicated Drug Combinations

  • Avoid concomitant MAOIs
  • Strong CYP3A4 inducers are NOT recommended (e.g., rifampin, carbamazepine, phenytoin) as they significantly reduce valbenazine levels 1

Contraindications

The only absolute contraindication is known hypersensitivity to valbenazine or any component of the formulation 1

Critical Warnings and Precautions

Boxed Warning: Depression and Suicidality (Huntington's Disease Only)

While this boxed warning applies specifically to Huntington's disease patients, exercise caution when treating patients with:

  • History of depression
  • Prior suicide attempts or ideation
  • Monitor closely for emergence or worsening of depression, suicidal thoughts, or unusual behavioral changes 1

Hypersensitivity Reactions

Discontinue immediately if angioedema or other serious hypersensitivity reactions occur 1

Somnolence/Sedation

  • Most common adverse effect (10.9% vs 4.2% placebo)
  • Number needed to harm = 15
  • Warn patients about impaired ability to drive or operate machinery 1, 2

QT Prolongation

  • Avoid use in patients with:
    • Congenital long QT syndrome
    • Arrhythmias associated with prolonged QT interval
  • Consider baseline and periodic ECG monitoring in at-risk patients 1

Neuroleptic Malignant Syndrome (NMS)

Discontinue immediately if NMS develops (rare but serious) 1

Parkinsonism

  • Post-marketing reports of severe parkinson-like symptoms
  • Reduce dose or discontinue if clinically significant parkinsonian signs develop 1

Monitoring Recommendations

Baseline Assessment

  • AIMS (Abnormal Involuntary Movement Scale) score to establish severity
  • Psychiatric history (depression, suicidality)
  • ECG if QT prolongation risk factors present
  • Hepatic function tests
  • CYP2D6 metabolizer status if available
  • Current medication review for drug interactions 3, 1

Ongoing Monitoring

  • AIMS assessment at regular intervals (e.g., weeks 4,6,12, then quarterly) to track response
  • Monitor for somnolence/sedation, especially during first weeks
  • Assess for emergence of depression or suicidal ideation
  • Watch for parkinsonian symptoms
  • Psychiatric stability in patients with schizophrenia or mood disorders 1, 4

Clinical Context and Evidence

The APA guideline provides a strong recommendation (1B) that patients with moderate to severe or disabling tardive dyskinesia be treated with a VMAT2 inhibitor 3. Valbenazine demonstrated significant efficacy in the pivotal KINECT 3 trial, with a mean reduction of -3.2 points on AIMS dyskinesia score at 80 mg/day versus -0.1 for placebo (p<0.001), yielding a number needed to treat of 4 2, 4.

The 80 mg dose is more effective than 40 mg and should be the target for most patients unless tolerability issues arise 4. Long-term studies confirm sustained efficacy and safety, with most patients requiring ongoing treatment 5. Recent data from KINECT-PRO demonstrate clinically meaningful improvements in quality of life measures beyond just movement reduction 6.

Common Pitfalls to Avoid

  • Don't skip the initial 40 mg week—titration is part of the FDA-approved regimen
  • Don't forget dose adjustments for hepatic impairment or drug interactions (this is a common prescribing error)
  • Don't use with strong CYP3A4 inducers—they render the medication ineffective
  • Don't confuse with deutetrabenazine dosing—valbenazine is once daily and doesn't require food
  • Don't discontinue antipsychotics in stable patients just because TD is being treated—psychiatric stability takes priority 3, 4

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.